Kornimate/medical-research-clean huggingface dataset:
effectiveness of percutaneous pulley release with infiltration, versus infiltration alone in trigger finders

Conditions: Trigger Finger

Summary: trigger finger is a mechanical problem characterized by pain and catching of digit in flexion. histological changes of a1 pulley and synovial proliferation have been identified as factors that prompt trigger finger the first-line treatment of trigger finger is conservative with splinting and corticosteroid injection. if the first infiltration fails, either a second infiltration or surgical sectioning of the pulley is proposed. surgery can be performed by several techniques (open section, percutaneous section with palpatory guidance, or under ultrasound guidance). percutaneous a1 pulley release under ultrasound guidance consists of cutting the a1 pulley by a percutaneous insertion with small needle under local anaesthesia. the hypothesis of the study is that percutaneous a1 pulley release under ultrasound guidance followed by a corticosteroid injection would be more effective than a second corticosteroid injection alone on complete resolution of the trigger finger symptoms


Eligibility criteria:
inclusion criteria: * patient ≥ 18 years old, * presence of a trigger finger (thumb or long fingers) to be treated * quinnell score \>1 * episode of trigger characterized on questioning or clinical examination * failure of a first corticosteroid infiltration \> 3 months before inclusion * first infiltration within 15 months of inclusion * thickening a1 pulley on ultrasound ≥ 0.5 mm * patient who has the capacity to understand the protocol and has given consent to participate in the research, * patient with social security coverage exclusion criteria: * presence of several symptomatic fingers requiring treatment by ultrasound-guided section of the pulley * patient who are pregnant, breastfeeding, or who have the potential to become pregnant without effective contraception at the time of inclusion * known allergy to corticoid (hydrocortancyl®) including its excipients ((benzyl alcohol, sodium carmellose, sodium chloride, polysorbate 80) * known allergies to lidocaine * ongoing anticoagulant treatments (avk, new oral anti-coagulants) * local or general infection, or suspicion of infection * live vaccines * evolving viruses (hepatitis, herpes, varicella, shingles) * severe or uncontrolled hypertension * unbalanced diabetes * underlying progressive cardiovascular disease * hemodialysis patients * prosthesis on the finger to be treated * echographic tendon fissure * inflammatory disease (rheumatoid arthritis, spondyloarthritis, connective tissue diseases, etc.) with tenosynovitis. * history of surgery on the fingers * dupuytren's disease * patient participating in another interventional clinical research protocol involving a drug or medical device * patient under guardianship, curators or legal protection
study of jmkx003948 ophthalmic suspension in healthy participants

Conditions: Age-Related Macular Degeneration (AMD); Diabetic Macular Edema (DME)

Summary: the study is a randomized, double-blind, placebo-controlled, phase 1 study of jmkx003948 ophthalmic suspension to evaluate the safety, tolerability and pk of single and multiple ascending doses in healthy participants. participant will be randomized to receive either jmkx003948 ophthalmic suspension (1%, 2%, 3% or 5%) or matching placebo (jmkx003948 ophthalmic suspension: placebo= 6: 2, n=8 per cohort). five cohorts (cohort 1-5) are planned. cohorts could also de-escalate to a lower concentration if current formulation was not tolerated (cohort 1b, 2b and 3b). in case of de-escalation, cohort 1b and 2b will continue to escalate to cohort 1c and cohort 2c, respectively. participants will be admitted to the site on day -1 after screening (up to 28 days), and remain domiciled until day 14 for cohort 1-4, day 8 for other cohorts.


Eligibility criteria:
inclusion criteria: 1. healthy adult males and/or females, 18 to 45 years of age (inclusive) at the date of signed consent form. 2. body mass index (bmi) greater than or equal to 18 and less than 32 (kg/m2) and a minimum body weight of 45 kg. 3. able to participate and comply with all study procedures and restrictions, and willing to provide written informed consent to participate in the study. 4. women of child-bearing potential and sexually active males willing to use highly effective methods of contraception from screening until 3 months after last dose of study drug. in addition, participants must not donate sperm/egg for the time period specified above. exclusion criteria: 1. history of disease of ocular surface, fundus, central nervous system, psychiatric and psychological condition, cardiovascular system, kidney, liver, digestive system, respiratory system, or metabolic/endocrine system, or other disease that in the opinion of the investigator (or medically qualified designee) may make participation unsafe for the participant or interfere with study evaluations. 2. any abnormal examination with clinical significance may interfere with study evaluations in opinion of the investigator (or medically qualified designee). 3. history of eye trauma or surgery including lasik/lasek. 4. any corrected visual acuity \< 20/20, or intraocular pressure ≥ 21 mmhg. 5. clinically significant abnormalities on ophthalmic examination that would hinder the assessment of the eye or data collection at the discretion of the investigator and/or ophthalmologist (or medically qualified designee).
influence of arrangement of small intestine order on the recovery of bowel function after laparoscopic colorectal surgery

Conditions: Postoperative Complications

Summary: the method of arranging and restoring the position of the small intestine under laparoscopy is used to determine whether it can promote the recovery of intestinal function after colorectal surgery.


Eligibility criteria:
inclusion criteria: * pathologically confirmed colorectal cancer, patients undergoing colon cancer or radical resection of high rectal cancer； * tumor stage (tnm): i-iii； * age: \>18 years old; \<80 years old; * asa: i-iii; * agree and sign the informed consent form. exclusion criteria: * stoma patients； * patients with preoperative intestinal obstruction； * constipation patients (more than three days before the last bowel movement)； * combined other organ resection patients； * stroke or spinal cord injury patients； * long-term opioid use patients； * patients with a history of previous abdominal surgery； * patients refused entry into the trial；
an evaluation of interlaminar lumbar instrumented (ilif™)

Conditions: Degenerative Disc Disease

Summary: patients diagnosed with single-level degenerative disc disease (ddd) of the lumbar spine undergo a posterior decompression followed by a fusion complete with a spinous process plate, graft, and a biologic.

interlaminar lumbar instrumented fusion (ilif™) is a compound surgical solution to spinal stenosis, combining direct neural decompression with an allograft interspinous spacer (extensure® h2) to maintain the segmental distraction, and a spinous process fixation plate (affix™) to maintain stability for eventual segmental fusion. because this compound solution requires only a midline incision rather than the far lateral exposure necessary in posterolateral fusion with pedicle screws, it is less invasive to the patient, and therefore should result in less postoperative pain and disability, broadening the applicability of the procedure to even those advanced in age or with existing comorbidities. subjects will be followed for 24 months following surgery to determine the changes in odi scores from preoperative to baseline assessments. this data will be compared to published data on similar procedures.

Eligibility criteria:
inclusion criteria: * patient is over 40 years of age; * patient is diagnosed with single-level lumbar degenerative disc disease between l1-l2 and l4-l5 with evidence of disc collapse and symptomatic claudication with or without back pain and requires surgical intervention; * patient is unresponsive to conservative treatment greater than or equal to six month 6 months, or exhibits progressive neurological symptoms in the face of conservative treatment; * patient is willing and able to comply with the requirements defined in the protocol for the duration of the study; * patient has signed and dated informed consent. exclusion criteria: * patients with lumbar pathologies requiring surgical treatment at more than one level; * patients with spondylolisthesis \> grade 1; * patients with lytic spondylolisthesis or a defect of the pars interarticularis; * patients with prior lumbar surgery at or adjacent to the operative level; * patients with spinal metastases or active spinal tumor malignancy; * progressive neuromuscular disease, e.g., muscular dystrophy, multiple sclerosis; * present chronic steroid use; * patients with rheumatoid arthritis or other autoimmune disease; * patients who are pregnant or interested in becoming pregnant within the follow-up period of the study; * patients with a history of substance abuse; * patients involved in active spinal litigation; * patients receiving workman's compensation for spinal conditions; * patients who are mentally incompetent; * patients who are incarcerated; * patients who are unwilling or unable to comply with the follow-up protocol schedule of visits and assessments.

Keywords: ddd decompression spinous process plate
gonadotropin releasing hormone antagonist in treatment of early-onset severe ovarian hyperstimulation syndrome

Conditions: Assisted Reproduction

Summary: efficacy of the use of gnrh antagonist in treatment of those who develop early-onset severe ovarian hyperstimulation syndrome and had cancelled embryo transfer


Eligibility criteria:
inclusion criteria: * women who develop early-onset severe ovarian hyperstimulation syndrome after controlled ovarian stimulation using long gnrh agonist protocol and hcg for triggering ovulation. exclusion criteria: * women on short or antagonist protocols. * women who received gnrh agonist for triggering ovulation. * women who had embryo transfer.
bevacizumab + triplet treatment for untreated with chemotherapy metastatic colorectal cancer

Conditions: Metastatic Colorectal Cancer

Summary: the purpose of this study is to evaluate the efficacy and safety of fluorouracil (5-fu), levofolinate calcium (l-lv), oxaliplatin (l-ohp) and irinotecan hydrochloride hydrate (cpt-11) (folfoxiri) plus bevacizumab in untreated metastatic colorectal cancer patients who harbor uridine diphosphate (udp)-glucuronosyl transferase 1a1 (ugt1a1) \*1/\*1, \*1/\*6 or \*1/\*28.


Eligibility criteria:
inclusion criteria: 1. histologically confirmed adenocarcinoma of the colon or rectum. 2. unresectable or recurrent colorectal cancer patient. 3. one or more measurable lesion in recist ver.1.1 criteria. 4. no prior chemotherapy, immunotherapy, and radiotherapy. 5. life expectancy at least 3 months. 6. patients who harbor ugt1a1\*1/\*1, \*1/\*6 or \*1/\*28. 7. the eastern cooperative oncology group (ecog) performance status of =\<1. 8. vital organ functions (listed below) are preserved within 14 days prior to entry. white blood cell count (wbc): \>= 3,000 per cubic millimeter neu: \>= 1,500 per cubic millimeter platelet count (plt): \>= 100,000 per cubic millimeter aspartate aminotransferase (ast/got) and alanine aminotransferase (alt/gpt): \<= 100 iu/l, \<= 150 iu/l in cases with liver metastasis t-bil: \<= 1.5 mg/dl serum creatinine: \<= 1.50 mg/dl proteinuria: \<= 1+ prothrombin time-international normalized ratio (pt-inr): \< 1.5 9. written informed consent. exclusion criteria: 1. vermiform appendix cancer and anal canal cancer. 2. administration of blood products/ granulocyte-colony stimulating factor (g-csf), and blood transfusion within 14 days prior to enrollment. 3. synchronous multiple malignancy or metachronous multiple malignancy less than 5 years disease free interval. 4. hepatitis b virus antigen (hbs-ag)(+), or hepatitis c virus antibody (hcv-ab)(+). 5. history of severe allergy. 6. sensory alteration or paresthesia interfering with function. 7. prior radiotherapy for ilium and abdomen. 8. infectious disease. 9. uncontrolled diarrhea. 10. ileus or bowel obstruction. 11. interstitial lung disease or pulmonary fibrosis. 12. malignant coelomic fluid required drainage. 13. administration of atazanavir sulfate. 14. heart disease to be clinically problem. 15. major surgical procedure or intestinal resection within 28 days prior to enrollment or colostomy within 14 days prior to enrollment. 16. known brain metastasis or strongly suspected of brain metastasis. 17. history of a thromboembolic disease. 18. receiving anti-platelet drugs. 19. poorly controlled gastrointestinal ulcer. 20. history of intestinal perforation within the past 12 months. 21. poorly controlled hypertension. 22. poorly controlled diabetes mellitus. 23. severe mental disorders. 24. women who are pregnant or nursing, men and women who wish to conceive a child or with no intention to contraception. 25. any other cases who are regarded as inadequate for study enrollment by investigators.

Keywords: bevacizumab oxaliplatin irinotecan hydrochloride hydrate fluorouracil levofolinate calcium
gentamicin treatment prior to schwannoma surgery - no residual function

Conditions: Vestibular Schwannoma

Summary: the purpose of the study is to determine whether vestibular and postural compensation following schwannoma surgery is improved by ablating vestibular function prior to surgery, even if vestibular function is absent according to modern assessment techniques

patients subjected to vestibular schwannoma surgery most often suffer from vertigo after surgery, even if no vestibular function can be found in pre-surgical assessment. according to retrospective data about 33% of patients scheduled for surgery do not have any measurable vestibular function. even the occurrence of spontaneous nystagmus has been recorded in patients with no or very little function prior to surgery (parietti-winkler et al. 2008 jnnp). this indicates that despite new methods of measuring vestibular function, remaining vestibular function can be present and patients might benefit from pre-treatment of gentamicin (tjernström et al. 2009 jnnp)

Eligibility criteria:
inclusion criteria: * vestibular schwannoma advised to surgical treatment * no measurable remaining vestibular function exclusion criteria: * impaired decision making * neurofibromatosis * signs for central dysfunction * remaining vestibular function * patients are advised not to participate in the gentamicin arm if * hearing is better than 30 decibel (db) in pure tone average (500, 1000, 2000, 3-4000 hz) and speech discrimination better than 70% * the neurosurgeon aim at hearing preservation surgery and do not want to risk gentamicin associated hearing loss

Keywords: vestibular schwannoma acoustic neuroma cerebellopontine angle tumour gentamicin rehabilitation postural balance
high flow nasal cannula and hypercapnia

Conditions: COPD

Summary: in the present investigation, in 50 copd with persistent hypercapnia after an acute exacerbation, the investigators want to assess the acceptability of hfnc and its effectiveness in further reducing the level of paco2, and to eventually verify the hypothesis, based on previous physiological studies, that the response to hfnc is dependent on the level of baseline hypercapnia and eventually on the presence of overlap syndrome. this latter parameters to eventually calculate the sample size and the target population to perform future definitive randomized long term trials vs niv.

fifthy copd patients inpatients recovering from an acute exacerbation of their disease and persisting hypercapnia, despite having reached a stabilization in ph (i.e. ph\>7,35 and paco2\>45 mmhg on 3 consecutive measurements) will be enrolled in the study after having signed a written informed consent osa/copd overlap syndrome was not considered and exclusion criteria and is defined as the presence of 15 or more obstructive respiratory events per hour of sleep, when a previous full night polysomnography (psg) was available or from a positive epworth questionnaire and a body mass index\>25 cardiac decompensation, restrictive thoracic disorders, renal insufficiency, cancer, and neurological disease were considered exclusion criteria. on day the patients will undergo a preliminary trial with hfnc to set the optimal flow, using the airvo2 (fisher \& paykel healthcare, auckland, new zealand). to this aim the patients will be asked to breathe keeping their mouth closed, as much as they could, at different levels of flow, starting from 20 l/min up to 40 if tolerated for a minimum of 15 minutes for each trial. at the end of this test the maximum level tolerated will be chosen as the flow to be set for the experimental procedure. temperature will be set according to the patient's tolerance starting from 34c, up to 37c, while fio2 will be kept constant to maintain an sao2 between 92 and 94%. from 9 am of day 2 to 9 am of day 5 (72 hours period), the patients will undergo hfnc for at least 8 hours/day and during the nightime. the nurse on shift will be in charge of supervising the adherence to this schedule and to report any violation of the protocol on a dedicated sheet. every morning at 10 am (1 hour after hfnc suspension) arterial blood gases (abgs), effective hours of hft and tolerance to the treatment as reported by the patient, using a dedicated scale where: )1. very bad 2. bad 3. moderate 4. good 5.very good) will be recorded

Eligibility criteria:
inclusion criteria: * inpatients recovering from an acute exacerbation of their disease * persisting hypercapnia, despite having reached a stabilization in ph (i.e. ph\>7,35 and paco2\>45 mmhg on 3 consecutive measurements) exclusion criteria: * cardiac decompensation, * restrictive thoracic disorders, * renal insufficiency, * cancer, * neurological disease
comparative study of anchoring-tip vs. conventional emr of colorectal polyps

Conditions: Colorectal Polyp

Summary: endoscopic mucosal resection (emr) is an effective and has been widely used technique for the treatment of superficial colorectal neoplasms. although, conventional emr (cemr) showed high efficacy for the management of colorectal superficial neoplasms, there is problematic limitation in this technique - incomplete resection. in literature, the anchoring-tip emr (aemr), named as "tip-in emr" was first introduced in 2016 from japan. recently, several retrospective studies have been suggested about the effectiveness of aemr. however, there has been no prospective randomized controlled study to identify its advantage over cemr. therefore, the investigators performed a multicenter randomized controlled trial to estimate the effectiveness of aemr compared with cemr for the endoscopic treatment of intermediate-size (10 to 20 mm) colorectal polyps.

after injection of normal saline solution mix, snaring was tried for cemr. in aemr, the snare tip was projected from the sheath by 1-2 mm length. consequently, a small mucosal incision was made at proximal side of lesion. then the snare was deployed progressively and adjusted around the lesion trying to obtain free margins. at the final step of both conventional and tip-in emr, the lesion was resected.

Eligibility criteria:
inclusion criteria: * intermediate-size (10 to 20 mm) colorectal polyps * morphologically sessile (is), slightly elevated (iia), flat (iib), and slightly depressed (iic) as paris classification of superficial neoplastic lesions * laterally spreading tumor (granular and nongranular type) as kudo classification. exclusion criteria: * pedunculated or excavated/ulcerated polyps * polyps with features strongly suggestive of submucosal invasive carcinoma * polyps in patients with inflammatory bowel disease, familial polyposis, electrolyte abnormality, and coagulopathy * residual lesions after endoscopic resection or presence of severe submucosal fibrosis.
telecommunications system in asthma

Conditions: Asthma

Summary: this project is investigating whether application of a telecommunications system to the care of adult patients with asthma will improve self-management by enhancing compliance with preventive medication regimens and fostering the use of peak-flow-based action plans.

background/rationale: asthma is one of the most common chronic diseases of adults, affecting 6% of the u.s. adult population and accounting for substantial morbidity and mortality. despite the availability of effective therapy for asthma, morbidity and mortality have increased over the last several decades. asthma specialty care, case management, and patient education are means for improving the quality of asthma care and patient outcomes, but cost and inconvenience limit the degree to which these are used in asthma care nationally. the principal aim of this study is to evaluate the impact of an inexpensive telephone-based home education and disease monitoring system on asthma medication adherence and clinical outcomes in adult patients with asthma. objective(s): we hypothesize that application of tlc to the care of adult patients with asthma will improve self-management by enhancing compliance with preventive medication regimens and fostering the use of peak flow-based action plans. this, in turn, will improve asthma control, thus reducing acute health care utilization and improving quality of life (qol). methods: a randomized controlled trial will be conducted with adult asthma patients identified from the va boston healthcare system comprised of the boston, west roxbury, and brockton va medical centers and their associated satellite clinics. patients will be randomized to either the tlc-asthma group or an attention placebo control group. outcome measurements will include medication adherence, qol, utilization of urgent care services, oral corticosteroid use.

Eligibility criteria:
inclusion criteria: * physician diagnosis of asthma * receiving treatment with one or more daily controller (i.e., preventive) medications * age = 18 years * less than 30 pack years of cigarette smoking * fevi greater than 50% of predicted * fevi bronchodilator response of at least 12% * ability to use a telephone without assistance exclusion criteria: n/a

Keywords: asthma disease management telecommunications health services quality of life patient compliance